$140.64
3.562.60%
At close: -
$140.60
-0.04-0.03%
After Hours: 7:30 PM EDT
Comments
Loading...
Latest news for Biogen (NASDAQ:BIIB) Stock
Biogen Stock (NASDAQ: BIIB)
Categories: All
Friday, February 21, 2025
Tuesday, February 18, 2025
Thursday, February 13, 2025
- Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts
- Scotiabank Maintains Sector Outperform on Bio...
- BMO Capital Maintains Market Perform on Bioge...
- Morgan Stanley Maintains Equal-Weight on Biog...
- Goldman Sachs Maintains Buy on Biogen, Lowers...
- RBC Capital Maintains Outperform on Biogen, L...
- Citigroup Maintains Neutral on Biogen, Lowers...
- Wells Fargo Maintains Equal-Weight on Biogen,...
- Biogen Analysts Lower Their Forecasts After Q4 Results
- HC Wainwright & Co. Maintains Buy on Biogen, ...
- Truist Securities Maintains Buy on Biogen, Lo...
- Forecasting The Future: 10 Analyst Projections For Biogen
- Canaccord Genuity Maintains Buy on Biogen, Lo...
- Needham Reiterates Hold on Biogento Hold
Wednesday, February 12, 2025
- Biogen Delivers Q4 Beat, Analyst Focuses On Leqembi Expansion, 2025 Outlook
- Stocks Trim Losses After Hot Inflation, Bonds Remain Pressured, Tesla Rebounds: What's Driving Markets Wednesday?
- Biogen shares are trading lower after the com...
- Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma
- Biogen Forecasts FY2025 Adjusted EPS Of $15.2...
- Biogen Q4 2024 Adj EPS $3.44 Beats $3.35 Esti...
- Royalty Pharma Entered Into An Agreement With...
- US Stocks Set For A Cautious Start Ahead Of Inflation Data: Expert Says 'Strong Bull Markets Tend To Roar Back To Life After Corrections'
- Earnings Scheduled For February 12, 2025
- Biogen Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Tuesday, February 11, 2025
Friday, January 31, 2025
Tuesday, January 28, 2025
Monday, January 27, 2025
Thursday, January 23, 2025
Tuesday, January 21, 2025
Friday, January 17, 2025
Tuesday, January 14, 2025
Monday, January 13, 2025
- Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts
- Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge
- Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday
- Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?
- Reported Saturday, Sage Therapeutics Confirms...